SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Vivjoa[™] (oteseconazole)

MEMBER & PRESCRIBER INFORMA	ATION: Authorization may be delayed if incomplete.				
Member Name:					
Member Sentara #:	Date of Birth:				
Prescriber Name:					
Prescriber Signature:					
Office Contact Name:					
none Number: Fax Number:					
DEA OR NPI #:					
DRUG INFORMATION: Authorization ma	ay be delayed if incomplete.				
Drug Form/Strength:					
Dosing Schedule:	Length of Therapy:				
Diagnosis:	ICD Code, if applicable:				
Veight: Date:					

Recommended Dosage:

Vulvovaginal candidiasis, recurrent:

- For Vivjoa only regimen: Oral:
 - O Day 1: 600 mg, as a single dose
 - o Day 2: 450 mg, as a single dose
 - Beginning on Day 14: Administer 150 mg once a week (every 7 days) for 11 weeks (Weeks 2 through 12)
- For Vivjoa and fluconazole regimen: Oral:
 - O Days 1 to 7: Fluconazole 150 mg, as a single dose, on days 1, 4, and 7
 - O Days 14 to 20: **Vivjoa** 150 mg once daily for 7 days
 - o Beginning on day 28: Vivjoa 150 mg once weekly for 11 weeks (Weeks 4 through 14)

Quantity Limits: 18 capsules per treatment course

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Authorization: Date of Service

A 11	· ·	4 1	C 11	•	• 4 •	4	1 4
AII	ለ† 1	the	tall	nwing	criteria	must	he met:
<u> </u>	UI I		1011	<u> </u>	CI I CI I II	HILAST	DC IIICL.

□ Member is ≥ 10 years of age
 □ Documentation member has diagnosis of recurrent vulvovaginal candidiasis with ≥3 episodes of vulvovaginal candidiasis (VVC) in a 12-month period
 □ Member is a biological female who is postmenopausal or has another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy)
 □ Member has tried and failed or has a contraindication or intolerance to maintenance antifungal therapy with oral fluconazole.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *